Matt Pierce
Direktor/Vorstandsmitglied bei LIfT BioSciences Ltd.
Aktive Positionen von Matt Pierce
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Downing Ventures
Downing Ventures Investment ManagersFinance Downing Ventures (Downing Ventures) is an independent venture capital firm founded in 1986. The firm is headquartered in London. | Private Equity Investor | 01.06.2021 | - |
Private-Equity-Analyst | 01.09.2019 | 01.06.2021 | |
Qkine Ltd.
Qkine Ltd. Pharmaceuticals: OtherHealth Technology Qkine Ltd. provides growth factors and bioactive proteins for use in stem cell science and regenerative medicine applications. Its products include Activin A and FGF2. The firm specializes in protein purification, organoids, cytokines, and protein-engineering. The company was founded by Marko Hyvonen and Catherine Elton in 2016 and is headquartered in Cambridge, the United Kingdom. | Direktor/Vorstandsmitglied | 01.11.2022 | - |
LIfT BioSciences Ltd.
LIfT BioSciences Ltd. Miscellaneous Commercial ServicesCommercial Services LIfT BioSciences Ltd. is a pre-clinical stage biotech company based in Brighton, UK. LIfT BioSciences is developing a first-in-class alpha neutrophil cell therapy called N-Lift, which is produced from a patented process using exceptional stem cells, a proprietary enhancement media, and genetic engineering. The therapy is designed to destroy solid tumors both directly and indirectly by turning the tumor microenvironment against the tumor and recruiting the rest of the immune system to destroy it. The British company is working with a range of pharmaceutical license partners across oncology, immunology, neurology, and AMR to develop a portfolio of immune-modulatory alpha neutrophils for treating a range of therapeutic indications, including solid tumors. The company's goal is to deliver complete remission in high unmet need solid tumors before the decade is out. The company was founded in 2014 by Alexander William Blyth, who was inspired to create the company after his mother passed away from pancreatic cancer. | Direktor/Vorstandsmitglied | 01.12.2019 | - |
TidalSense Ltd.
TidalSense Ltd. Medical SpecialtiesHealth Technology Part of Gas Sensing Solutions Ltd., Cambridge Respiratory Innovations Ltd. develops and manufactures medical devices. The private company is based in Swavesey, UK. | Direktor/Vorstandsmitglied | 01.08.2021 | - |
Karriereverlauf von Matt Pierce
Ausbildung von Matt Pierce
The University of Edinburgh | Undergraduate Degree |
Statistik
International
Vereinigtes Königreich | 6 |
Operativ
Director/Board Member | 3 |
Private Equity Analyst | 1 |
Private Equity Investor | 1 |
Sektoral
Health Technology | 3 |
Finance | 2 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 4 |
---|---|
Downing Ventures
Downing Ventures Investment ManagersFinance Downing Ventures (Downing Ventures) is an independent venture capital firm founded in 1986. The firm is headquartered in London. | Finance |
Qkine Ltd.
Qkine Ltd. Pharmaceuticals: OtherHealth Technology Qkine Ltd. provides growth factors and bioactive proteins for use in stem cell science and regenerative medicine applications. Its products include Activin A and FGF2. The firm specializes in protein purification, organoids, cytokines, and protein-engineering. The company was founded by Marko Hyvonen and Catherine Elton in 2016 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
TidalSense Ltd.
TidalSense Ltd. Medical SpecialtiesHealth Technology Part of Gas Sensing Solutions Ltd., Cambridge Respiratory Innovations Ltd. develops and manufactures medical devices. The private company is based in Swavesey, UK. | Health Technology |
LIfT BioSciences Ltd.
LIfT BioSciences Ltd. Miscellaneous Commercial ServicesCommercial Services LIfT BioSciences Ltd. is a pre-clinical stage biotech company based in Brighton, UK. LIfT BioSciences is developing a first-in-class alpha neutrophil cell therapy called N-Lift, which is produced from a patented process using exceptional stem cells, a proprietary enhancement media, and genetic engineering. The therapy is designed to destroy solid tumors both directly and indirectly by turning the tumor microenvironment against the tumor and recruiting the rest of the immune system to destroy it. The British company is working with a range of pharmaceutical license partners across oncology, immunology, neurology, and AMR to develop a portfolio of immune-modulatory alpha neutrophils for treating a range of therapeutic indications, including solid tumors. The company's goal is to deliver complete remission in high unmet need solid tumors before the decade is out. The company was founded in 2014 by Alexander William Blyth, who was inspired to create the company after his mother passed away from pancreatic cancer. | Commercial Services |
- Börse
- Insiders
- Matt Pierce
- Erfahrung